Fig. 4: Anti-G mAbs display protection in hamsters against NiV infection.

A Prophylactic or therapeutic treatment schemes of NiV mAbs in hamsters. For prophylactic treatment, hamsters (n = 6) were administered the indicated mAbs at 30 mg/kg via the intraperitoneal route and then challenged with the NiV_M strains at 1000 LD₅₀ via an intraperitoneal route 24 h later. For therapeutic treatment, hamsters (n = 6) were challenged with the NiV_M strains at 1000 LD₅₀ via an intraperitoneal route and then administered the indicated mAbs via the intraperitoneal route at 15 mg/kg twice (day 1 and 3 post-challenge). B, C Survival (B) and weight change (C) of Syrian hamsters during the prophylactic treatment regime. D, E Survival (D) and weight change (E) of Syrian hamsters during the therapeutic treatment regime. Data in each group are presented as mean and standard deviation (SD) in (C) and (E).